Physician profile
Olufunke Afolabi-Brown
NPI 1912190547
$92,665.57
in general payments reported to CMS, 2019-2025
8 companies · $92K in 2025
The $92K reported for 2025 was more than what 99% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $136 · 2024: $333 · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Consulting Fee: $15K · Travel and Lodging: $12K · Food and Beverage: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,662.50 |
| Consulting Fee | $15,162.50 |
| Travel and Lodging | $11,785.15 |
| Food and Beverage | $2,055.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $83,575.91 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $5,450.00 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $3,096.62 | 2024-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $242.25 | 2023-2025 | Xywav |
| Harmony Biosciences LLC | $130.51 | 2024-2025 | |
| Biocryst US Sales Co., LLC | $127.49 | 2024 | Orladeyo |
| Vertex Pharmaceuticals Incorporated | $25.61 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $17.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olufunke Afolabi-Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.